Stable Isotope Labeling-Based Nontargeted Strategy for Characterization of the In Vitro Metabolic Profile of a Novel Doping BPC-157 in Doping Control by UHPLC-HRMS.
Level 5 - mechanism / opinion, no new human data
In vitro bench research and analytical method validation without in vivo human clinical data.
PubMed 37959764 · doi:10.3390/molecules28217345
What was done
Researchers developed an in vitro metabolic profiling and detection workflow for the novel doping agent BPC-157 using stable isotope labeling (13C/15N-labeled BPC-157) paired with ultra-high-performance liquid chromatography-high-resolution mass spectrometry (UHPLC-HRMS). The automated isotopic pair-picking approach was tested across two incubation models, and an analytical detection method was validated for parent BPC-157 and its primary metabolites in human urine.
What was found
The platform identified nine in vitro metabolites: eight generated by traditional amide-bond cleavage and one produced via a newly characterized metabolic pathway. An assay developed for BPC-157 and five key metabolites in human urine achieved limits of detection between 0.01 and 0.11 ng/mL, linearity from 0.02 to 50 ng/mL (R2 > 0.999), relative error < 10%, relative standard deviation < 5%, and recovery > 90%.
Why it matters
This provides anti-doping laboratories with validated analytical targets and a sensitive mass spectrometry method to detect illicit BPC-157 use in urine samples.
Limits
The study is restricted entirely to in vitro incubation systems and spiked urine validation; no in vivo human pharmacokinetic, administration, or excretion studies were conducted, leaving real-world detection windows undetermined.
Cited by
- supports BPC-157 is included on the World Anti-Doping Agency (WADA) prohibited list.